- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04224974
Ensaio de Engajamento Focado na Emoção e no Sintoma para Indivíduos com Leucemia Aguda (EASE)
Engajamento Focado na Emoção e no Sintoma (EASE): Um Estudo Controlado Randomizado em Vários Locais de uma Intervenção para Indivíduos com Leucemia Aguda
The purpose of this study is to find out whether a novel manualized intervention, called Emotion and Symptom-focused Engagement (EASE), that combines psychological support with symptom screening plus triggered referral to early palliative care for symptom control, reduces psychological distress and physical symptom burden in individuals newly diagnosed with acute leukemia. To do this, half of the participants in this study will receive the usual care offered to patients with acute leukemia and half of the participants will receive usual care plus the EASE intervention.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The standard or usual care treatment for patients with newly diagnosed acute leukemia involves admission to hospital for treatment (e.g. induction chemotherapy). Additional support services may be delivered if requested or if a doctor thinks it is necessary.
Little research has been done looking at the psychological and physical consequences of being diagnosed with and treated for acute leukemia, but our research team has found that a significant number of these individuals experience symptoms of traumatic stress and severe physical symptoms. Even less research has been done looking at ways to help alleviate this psychological and physical distress. Emotion and Symptom-focused Engagement (EASE) is an integrated psychosocial and early palliative care (symptom control) intervention designed to reduce psychological distress and physical symptom burden in patients newly diagnosed with acute leukemia. The EASE intervention provides i) tailored supportive psychotherapy (called EASE-psy) during the initial weeks of treatment to reduce symptoms of traumatic stress, and ii) symptom screening during the initial inpatient treatment period with triggered referral to early palliative care (symptom control) to help manage moderate to severe physical symptoms (called EASE-phys).
A phase II trial of EASE in patients with newly diagnosed acute leukemia demonstrated feasibility and preliminary evidence that it reduces psychological distress and physical symptom severity compared to usual care. This new trial is a definitive phase III, multi-site randomized controlled trial to test the effectiveness of EASE at reducing psychological distress and physical burden.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Harriet Richardson
- Número de telefone: 613-533-6430
- E-mail: hrichardson@ctg.queensu.ca
Estude backup de contato
- Nome: Lois Shepherd
- Número de telefone: 613-533-6430
- E-mail: lshepherd@ctg.queensu.ca
Locais de estudo
-
-
New Brunswick
-
Saint John, New Brunswick, Canadá, E2L 4L2
- Recrutamento
- Regional Health Authority B, Zone 2
-
Contato:
- Alfonso Rivera Duarte
- Número de telefone: 506 648-7109
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8V 5C2
- Recrutamento
- Juravinski Cancer Centre at Hamilton Health Sciences
-
Contato:
- Alejandro Garcia-Horton
-
Kingston, Ontario, Canadá, K7L 2V7
- Recrutamento
- Kingston Health Sciences Centre
-
Contato:
- Annette Hay
- Número de telefone: 77094 613 533-6430
-
Ottawa, Ontario, Canadá, K1H 8L6
- Recrutamento
- Ottawa Hospital Research Institute
-
Contato:
- Pierre Villeneuve
- Número de telefone: 613
-
Toronto, Ontario, Canadá, M5G 2M9
- Recrutamento
- University Health Network
-
Contato:
- Gary Rodin
- Número de telefone: 416 946-4504
-
Toronto, Ontario, Canadá, M4N 3M5
- Recrutamento
- Odette Cancer Centre
-
Contato:
- Lee Mozessohn
- Número de telefone: 5847 416 480-5000
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Newly diagnosed AL (acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) chronic myelogenous leukemia (CML) in blast crisis; T-cell leukemia lymphoma (TLL), and AL of ambiguous lineage) and is recruited up to 1 week prior to hospital admission or within 2 weeks of hospital admission. For patients diagnosed with a mixed phenotype AL, the dominant sub-type must be identified for stratification purposes.
- Receiving or expected to receive induction therapy with curative intent at the time of recruitment.
- Age ≥ 18 years.
- Ability to pass the cognitive screening test at the time of recruitment (Short Orientation-Memory-Concentration Test (SOMC) score ≥ 20), unless deemed suitable at the CRA's discretion (e.g. in extenuating circumstances such as interruptions during the administration of the measure or when patients report a learning disability that can influence the results).
- Patient is fluent in English and is able (i.e. sufficiently literate and competent) and willing to complete the baseline questionnaires in English. Ability but unwillingness to complete the baseline questionnaires will make the patient ineligible.
Exclusion Criteria:
- Major communication difficulties at the time of recruitment, as assessed by the research team (e.g. severe hearing impairment or inability to speak).
- Receiving on-site (in hospital) psychological/psychiatric counseling at the time of recruitment.
- Receiving on-site (in hospital) palliative care services at the time of recruitment.
- A diagnosis of acute promyelocytic leukemia.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Outros: Cuidados habituais
|
The usual care group will receive usual care of their acute leukemia at their centre but no formal psychological or palliative care intervention as part of this trial |
|
Experimental: Behavioral: Usual Care + EASE Intervention-psy
EASE Intervention = EASE-psy + EASE-phys |
All patients randomized to EASE will receive tailored supportive psychotherapy over the initial 8 weeks following the diagnosis of acute leukemia. The psychotherapy will be delivered by trained therapists and combines elements of relational support, affect regulation, and trauma-informed cognitive behavioural therapy (CBT). -EASE-phys: All patients randomized to EASE will receive weekly symptom screening during the initial inpatient treatment period (typically 4 weeks) with triggered referral to early palliative care (symptom control) to help manage moderate to severe physical symptoms based on a philosophy of multidisciplinary care and comprehensive assessment of symptoms. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Assess the effect of the EASE intervention compared to usual care to reduce traumatic stress symptoms using the Stanford Acute Stress Reaction questionnaire (SASRQ)
Prazo: 4 weeks
|
This 30-item measure assesses severity of traumatic stress symptoms over the past four weeks; it has been updated to be Diagnostic and Statistical Manual of Mental Disorders (DSM-5)-concordant [American Psychiatric Association 2013] for acute stress disorder (ASD). Mean severity of traumatic stress symptoms at 4 weeks will be the first primary outcome |
4 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Avalie o efeito da intervenção EASE em comparação com os cuidados habituais para reduzir os sintomas de estresse traumático usando o SASRQ
Prazo: 8 semanas, 12 semanas e 26 semanas
|
8 semanas, 12 semanas e 26 semanas
|
|
|
Avalie o efeito da intervenção EASE nos cuidados habituais para reduzir a gravidade dos sintomas físicos usando o MSAS
Prazo: 8 semanas, 12 semanas e 26 semanas
|
8 semanas, 12 semanas e 26 semanas
|
|
|
Avalie o efeito da intervenção EASE em comparação com os cuidados habituais no número de participantes que atendem aos critérios consistentes com um diagnóstico de TEA e TEA limiar com base nos critérios do DSM-5 usando o SASRQ
Prazo: 4, 8, 12 e 26 semanas
|
4, 8, 12 e 26 semanas
|
|
|
Avalie o efeito da intervenção EASE em comparação com os cuidados habituais sobre o número de sintomas físicos de câncer e o desconforto relacionado aos sintomas associados, conforme medido pelo (MSAS)
Prazo: 4, 8, 12 e 26 semanas
|
4, 8, 12 e 26 semanas
|
|
|
Avalie o efeito da intervenção EASE em comparação com os cuidados habituais na satisfação do paciente com o atendimento usando o FAMCAR-P16 de 16 itens
Prazo: 4, 8, 12 e 26 semanas
|
4, 8, 12 e 26 semanas
|
|
|
10) O EQ-5D-5L será usado para medir o estado de saúde genérico para que possa ser usado para calcular anos de vida ajustados pela qualidade (QALY) em uma avaliação econômica que compara o benefício e o custo da intervenção EASE
Prazo: 4, 8, 12, 26 e 52 semanas
|
4, 8, 12, 26 e 52 semanas
|
|
|
Para comparar a sobrevida livre de progressão entre os braços de tratamento
Prazo: 1 ano
|
1 ano
|
|
|
Assess the effect of the EASE intervention compared to usual care to reduce physical symptom severity using the Memorial Symptom Assessment Scale (MSAS)
Prazo: 4 weeks
|
This reliable and valid instrument assesses symptom prevalence, severity and distress associated with 26 common physical and 6 psychological symptoms of cancer. Mean physical symptom severity at 4 weeks will be the second primary outcome |
4 weeks
|
|
Assess the effect of the EASE intervention compared to usual care on Quality of Life using The Functional Assessment of chronic Illness Therapy-Spiritual Well-being Scale
Prazo: 4, 8, 12, 26 and 52 weeks
|
Individual subscales of the FACIT-Sp provide scores for physical, social/family, emotional, functional spiritual well-being |
4, 8, 12, 26 and 52 weeks
|
|
Assess the effect of the EASE intervention compared to usual care on depressive symptoms using The Patient Health Questionnaire-9 (PHQ-9)
Prazo: 4, 8 ,12 and 26 weeks
|
This valid 9-item measure of depression has been widely used with patients with advanced cancer. Two additional items assessing intent to cause self-harm and interference with daily activities were included in the measure to ensure patients' safety but are not considered for data analysis. |
4, 8 ,12 and 26 weeks
|
|
Assess the effect of the EASE intervention compared to usual care on pain using the modified Brief Pain Inventory-Sort Form (BPI)
Prazo: 4, 8 12 and 26 weeks
|
The BPI is a widely used measure to rapidly assess the severity of pain and its impact on functioning and will be assessed as part of the secondary outcomes |
4, 8 12 and 26 weeks
|
|
The modified brief Experiences in Close Relationships Scale (ECR-M16) is an instrument to measure attachment security or the ability to rely on close others for support when distressed.
Prazo: Baseline
|
It provides subscale scores assessing attachment anxiety (i.e. fear of abandonment) and attachment avoidance (i.e. defensive independence). The ECR-M16 will only be administered at baseline in both arms of the study. |
Baseline
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Cadeira de estudo: Gary Rodin, Princess Margaret Hospital, Canada
- Cadeira de estudo: Camilla Zimmerman, Princess Margaret Hospital, Canada
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- SC26
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .